期刊文献+

SIRT1和p53在子宫内膜癌中的表达及其临床意义 被引量:1

原文传递
导出
摘要 目的研究沉默信息调节因子1(SIRT1)和p53在子宫内膜癌(EC)中的表达情况,分析SIRT1与p53的相关性,并探讨其临床和病理学意义。方法应用免疫组织化学方法检测95例EC、40例正常子宫内膜组织中SiRT1和053的表达情况,并结合临床、病理学因素进行分析。结果SIRT1和053在EC中的阳性率分别为83.2%(79/95)、49.5%(47/95);在正常子宫内膜组织中的阳性率分别为17.5%(7/40)、7.5%(3/40),EC均高于正常子宫内膜组织,差异有统计学意义(X^2=52.480,X^2=21.266,P均〈0.001);SIRT1的表达在晚期、分化差EC的阳性率高于早期、分化好的阳性率(X^2=8.011,P=0.018;)(2=8.172,P=0.017);p53在Ⅱ型、分期晚、分化差、浸润深度≥1/2、有淋巴结转移的阳性率较高,差异有统计学意义(P均〈0.05)。SIRT1与p53呈正相关(r=0.292,P=0.004)。结论SIRT1是EC的肿瘤促进因子,SIRT1和p53可能参与EC的形成和增殖,并可能成为判断肿瘤恶性程度及预后的指标;联合检测SIRT1、053有助于判断预后、指导临床治疗。
出处 《中国综合临床》 2013年第1期93-96,共4页 Clinical Medicine of China
  • 相关文献

参考文献10

  • 1Dobrzycka B, Terlikowski S J, Garbowicz M. The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer [J]. Folia Histochem Cytobiol,2011, 49(4) :631-635,.
  • 2Yi J, Luo J. SIRT1 and p53, effect on cancer, senescence and beyond [J]. Biochim Biophys Acta,2010,1804 ( 8 ) : 1684-1689.
  • 3Tavassoli FA, Devilee P. World Health Organization: Tumours of the breast and female genital organs [M]. 3rd ed. Lyon: IARC Press-WHO ,2003:221-227.
  • 4Maiese K, Chong ZZ, Shang YC, et al. Translating cell survival and cell longevity into treatment strategies with SIRT1. [J]. Rom J Morphol Embryol,2011,52 (4) : 1173-1185.
  • 5Inoue Y,Iemura S, Natsume T, et al. Suppression of p53 activity through the cooperative action of Ski and histone deaeetylase SIRT1 [J]. J Biol Chem,2011,286(8) :6311-6320.
  • 6卢洪胜,甘梅富,张艳,成斌,蔡菊芳,周涛.宫颈癌前病变及宫颈癌组织Survivin和p16^(INK4A)及p53表达的研究[J].中华肿瘤防治杂志,2009,16(11):810-813. 被引量:14
  • 7杨其昌,朱燕,刘宏斌,张晓娟,季晓华,沈屹.宫颈上皮内瘤变p16^(INK4a)和p53及Ki-67表达及其诊断价值探讨[J].中华肿瘤防治杂志,2011,18(16):1255-1258. 被引量:10
  • 8Audrito V, Vaisitti T, Rossi D, et al. Nieotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network [ J]. Cancer Res ,2011,71 (13) :4473-4483.
  • 9Shah ZH, Ahmed SU, Ford JR, et al. A deacetylase-deficient SIRT1 variant opposes fuU-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes [J]. Mol Cell Biol,2012,32(3) :704-716.
  • 10Jemal A,Siegel R, Ward E, et al. Cancer statistics,2009 [J]. CA Cancer J Clin,2009,59(4) :225-249.

二级参考文献27

  • 1郑金锋,马淑芳,耿明,曹永成,刘莹.p16和p15及PCNA在子宫颈癌组织中的表达及临床病理意义[J].中华肿瘤防治杂志,2007,14(4):291-293. 被引量:15
  • 2官立丽,彭芝兰,牛晓宇.HPV16 E6小干扰RNA与宫颈癌细胞中E6 p53 p21关系的研究[J].中国实用妇科与产科杂志,2007,23(7):517-519. 被引量:4
  • 3Schell W M, Janicek M F, Mirhashemi R. Epidemiology and bi ology of cervical cancer[J]. Semin Surg Oneol, 1999, 16(3):203-211.
  • 4Miehael F, Elka A, David O, et al. Immunohistochemical localization of survivin in benign eerdcal mucosa, cervical dysplasia, and invasive squamous cell carcinoma[J]. Am J Clin Pathol, 2002,117(5) :738.
  • 5Kim H S, Shiraki K, Park S H. Expression of survivin in CIN and invasive squamous cell carcinoma ofuterine cervix[J]. Antieancer Research, 2002, 22 (2) :805.
  • 6Ambrosch P, Schlott T, Hitmes D, et al. P16 alterations and retinohlastoma protein expression in squamous cell carcinoma and neighboring dysplasia from the upper aerodigestive tract[J]. Virchows Arch, 2001, 438(4): 343 349.
  • 7Ding L, Zou X J, Ao J E, et al. ELISA test to detect CDKN2A [p16(INK4a)] expression in exfoliative cells: a new screening tool for cervicalcancer[J]. MolDiagnTher, 2008, 12(6): 395-400.
  • 8Ozgul N, Cil A P, Bozdayi G. Staining characteristics of p16INK4A: is there a correlation with lesion grade or high-risk human papilloma virus positivity[J]. J Obstet Gynaecol Res,2008, 34(5):865-871.
  • 9Negn G, Egarter-Vigl E, kasal A, et al. p16^INK4A is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations[J]. Am J Surg Pathol, 2003, 27(2) : 187-193.
  • 10Tommasino M, Accardi R, Caldeira S, et al. The role of TP53 in cervicalcareinogenesis[J]. Hum Mutat, 2003, 21 (3): 307-312.

共引文献22

同被引文献11

  • 1Kim JE,Sung S.Deleted in breast cancer 1(DBC1)is adynamically regulated protein[J].Neoplasma,2010,57(4):365-368.
  • 2Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CACancer J Clin,2013,63(1):11-30.
  • 3Chini EN,Chini CC,Nin V,et al.Deleted in breast cancer-1(DBC-1)in the interface between metabolism,aging and cancer[J].Biosci Rep,2013,33(4):637-643.
  • 4Song NY,Surh YJ.Janus-faced role of SIRT1 in tumorigenesis[J].Ann N Y Acad Sci,2012,1271:1049.
  • 5Zhang Y,Gu Y,Sha S,et.al.DBC1 is over-expressed andassociated with poor prognosis in colorectal cancer[J].Int J Clin Oncol,2014,19(1):106-112.
  • 6Bae HJ,Chang YG,Noh JH,et al.DBC1 does not function as a negative regulator of SIRT1 in liver cancer[J].Oncol Lett,2012,4(5):873-877.
  • 7Kang Y,Jung WY,Lee H,et al.Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma[J].Korean J Pathol,2012,46(6):523-531.
  • 8Yu XM,Liu Y,Jin T,et al.The Expression of SIRT1 and DBC1 in Laryngeal and Hypopharyngeal Carcinomas[J].PLoS One,2013,8(6):e66975.
  • 9SKim UJ,Lee IS,Kang HW,et al Decreased DBCl Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer[J].Korean J Urol,2013,54(9):631-637.
  • 10陶春英,张婷,杨晓娟,李云芬,聂建云.DBC1的研究进展[J].现代肿瘤医学,2013,21(7):1653-1655. 被引量:4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部